111 related articles for article (PubMed ID: 10406646)
1. Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.
Miller WH; Bondinell WE; Cousins RD; Erhard KF; Jakas DR; Keenan RM; Ku TW; Newlander KA; Ross ST; Haltiwanger RC; Bradbeer J; Drake FH; Gowen M; Hoffman SJ; Hwang SM; James IE; Lark MW; Lechowska B; Rieman DJ; Stroup GB; Vasko-Moser JA; Zembryki DL; Azzarano LM; Adams PC; Huffman WF
Bioorg Med Chem Lett; 1999 Jul; 9(13):1807-12. PubMed ID: 10406646
[TBL] [Abstract][Full Text] [Related]
2. Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics.
Keenan RM; Miller WH; Barton LS; Bondinell WE; Cousins RD; Eppley DF; Hwang SM; Kwon C; Lago MA; Nguyen TT; Smith BR; Uzinskas IN; Yuan CC
Bioorg Med Chem Lett; 1999 Jul; 9(13):1801-6. PubMed ID: 10406645
[TBL] [Abstract][Full Text] [Related]
3. Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis.
Lark MW; Stroup GB; Hwang SM; James IE; Rieman DJ; Drake FH; Bradbeer JN; Mathur A; Erhard KF; Newlander KA; Ross ST; Salyers KL; Smith BR; Miller WH; Huffman WF; Gowen M
J Pharmacol Exp Ther; 1999 Nov; 291(2):612-7. PubMed ID: 10525079
[TBL] [Abstract][Full Text] [Related]
4. Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.
Miller WH; Alberts DP; Bhatnagar PK; Bondinell WE; Callahan JF; Calvo RR; Cousins RD; Erhard KF; Heerding DA; Keenan RM; Kwon C; Manley PJ; Newlander KA; Ross ST; Samanen JM; Uzinskas IN; Venslavsky JW; Yuan CC; Haltiwanger RC; Gowen M; Hwang SM; James IE; Lark MW; Rieman DJ; Stroup GB; Azzarano LM; Salyers KL; Smith BR; Ward KW; Johanson KO; Huffman WF
J Med Chem; 2000 Jan; 43(1):22-6. PubMed ID: 10633035
[No Abstract] [Full Text] [Related]
5. Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.
Miller WH; Manley PJ; Cousins RD; Erhard KF; Heerding DA; Kwon C; Ross ST; Samanen JM; Takata DT; Uzinskas IN; Yuan CC; Haltiwanger RC; Gress CJ; Lark MW; Hwang SM; James IE; Rieman DJ; Willette RN; Yue TL; Azzarano LM; Salyers KL; Smith BR; Ward KW; Johanson KO; Huffman WF
Bioorg Med Chem Lett; 2003 Apr; 13(8):1483-6. PubMed ID: 12668017
[TBL] [Abstract][Full Text] [Related]
6. Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis.
Coleman PJ; Brashear KM; Askew BC; Hutchinson JH; McVean CA; Duong LT; Feuston BP; Fernandez-Metzler C; Gentile MA; Hartman GD; Kimmel DB; Leu CT; Lipfert L; Merkle K; Pennypacker B; Prueksaritanont T; Rodan GA; Wesolowski GA; Rodan SB; Duggan ME
J Med Chem; 2004 Sep; 47(20):4829-37. PubMed ID: 15369386
[TBL] [Abstract][Full Text] [Related]
7. Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. II. Studies implicating transporter-mediated intestinal secretion.
Ward KW; Hardy LB; Kehler JR; Azzarano LM; Smith BR
Xenobiotica; 2004 Apr; 34(4):367-77. PubMed ID: 15268981
[TBL] [Abstract][Full Text] [Related]
8. Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model.
Keenan RM; Lago MA; Miller WH; Ali FE; Cousins RD; Hall LB; Hwang SM; Jakas DR; Kwon C; Louden C; Nguyen TT; Ohlstein EH; Rieman DJ; Ross ST; Samanen JM; Smith BR; Stadel J; Takata DT; Vickery L; Yuan CC; Yue TL
Bioorg Med Chem Lett; 1998 Nov; 8(22):3171-6. PubMed ID: 9873697
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial chemistry techniques applied to nonpeptide integrin antagonists.
Hoekstra WJ; Poulter BL
Curr Med Chem; 1998 Jun; 5(3):195-204. PubMed ID: 9562602
[TBL] [Abstract][Full Text] [Related]
10. Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis.
Badger AM; Blake S; Kapadia R; Sarkar S; Levin J; Swift BA; Hoffman SJ; Stroup GB; Miller WH; Gowen M; Lark MW
Arthritis Rheum; 2001 Jan; 44(1):128-37. PubMed ID: 11212150
[TBL] [Abstract][Full Text] [Related]
11. Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat.
Lark MW; Stroup GB; Dodds RA; Kapadia R; Hoffman SJ; Hwang SM; James IE; Lechowska B; Liang X; Rieman DJ; Salyers KL; Ward K; Smith BR; Miller WH; Huffman WF; Gowen M
J Bone Miner Res; 2001 Feb; 16(2):319-27. PubMed ID: 11204432
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and characterization of orally active nonpeptide vasopressin V2 receptor antagonists.
Ohkawa T; Zenkoh T; Tomita M; Hosogai N; Hemmi K; Tanaka H; Setoi H
Chem Pharm Bull (Tokyo); 1999 Apr; 47(4):501-10. PubMed ID: 10319429
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist.
Ward KW; Azzarano LM; Bondinell WE; Cousins RD; Huffman WF; Jakas DR; Keenan RM; Ku TW; Lundberg D; Miller WH; Mumaw JA; Newlander KA; Pirhalla JL; Roethke TJ; Salyers KL; Souder PR; Stelman GJ; Smith BR
Drug Metab Dispos; 1999 Nov; 27(11):1232-41. PubMed ID: 10534306
[TBL] [Abstract][Full Text] [Related]
14. Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 2: design of potent antagonists containing the 3-azaspiro[5.5]undecanes.
Pandey A; Seroogy J; Volkots D; Smyth MS; Rose J; Mehrotra MM; Heath J; Ruhter G; Schotten T; Scarborough RM
Bioorg Med Chem Lett; 2001 May; 11(10):1293-6. PubMed ID: 11392540
[TBL] [Abstract][Full Text] [Related]
15. Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonists.
Keenan RM; Miller WH; Lago MA; Ali FE; Bondinell WE; Callahan JF; Calvo RR; Cousins RD; Hwang SM; Jakas DR; Ku TW; Kwon C; Nguyen TT; Reader VA; Rieman DJ; Ross ST; Takata DT; Uzinskas IN; Yuan CC; Smith BR
Bioorg Med Chem Lett; 1998 Nov; 8(22):3165-70. PubMed ID: 9873696
[TBL] [Abstract][Full Text] [Related]
16. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
Ohlstein EH; Nambi P; Lago A; Hay DW; Beck G; Fong KL; Eddy EP; Smith P; Ellens H; Elliott JD
J Pharmacol Exp Ther; 1996 Feb; 276(2):609-15. PubMed ID: 8632328
[TBL] [Abstract][Full Text] [Related]
17. Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. I. Investigation of potential experimental and mechanistic explanations.
Ward KW; Azzarano LM; Evans CA; Smith BR
Xenobiotica; 2004 Apr; 34(4):353-66. PubMed ID: 15268980
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
[TBL] [Abstract][Full Text] [Related]
19. alpha(v)beta(3) Antagonists based on a central thiophene scaffold.
Peyman A; Scheunemann K; Will DW; Knolle J; Wehner V; Breipohl G; Stilz HU; Carniato D; Ruxer J; Gourvest J; Auberval M; Doucet B; Baron R; Gaillard M; Gadek TR; Bodary S
Bioorg Med Chem Lett; 2001 Aug; 11(15):2011-5. PubMed ID: 11454469
[TBL] [Abstract][Full Text] [Related]
20. Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonists.
Keenan RM; Miller WH; Kwon C; Ali FE; Callahan JF; Calvo RR; Hwang SM; Kopple KD; Peishoff CE; Samanen JM; Wong AS; Yuan CK; Huffman WF
J Med Chem; 1997 Jul; 40(15):2289-92. PubMed ID: 9240343
[No Abstract] [Full Text] [Related]
[Next] [New Search]
